Stock Report

All about this stock under one free report Last Updated: 17-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Virios Therapeutics Inc. (VIRI)

Stock Card factsheet share-fund-plan-icon

$2.74

up-down-arrow $0.37 (15.61%)

As on 10-Dec-2024 09:30EDT

Market cap

info icon

$0 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

3.3

Div. Yield

info icon

0 %

Virios Therapeutics (VIRI) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.47 High: 2.74

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -1.2 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    0.2

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    1,332,270

6 Years Aggregate

CFO

$-39.21 Mln

EBITDA

$-47.55 Mln

Net Profit

$-48.67 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Virios Therapeutics (VIRI)
-80.9 -36.3 -39.4 -83.9 -71.3 -- --
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 10-Dec-2024  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2023
2022
2021
Virios Therapeutics (VIRI)
143.6 -95.4 -31.9
S&P Small-Cap 600
13.9 -17.4 25.3
BSE Sensex
18.7 4.4 22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Virios Therapeutics (VIRI)
2.7 0.2 0.0 -4.7 -- -134.8 -- 3.3
Longboard Pharmaceuticals (LBPH)
60.0 2,342.0 0.0 -76.3 -1,093,125.0 -25.9 -- 8.5
Lumos Pharma (LUMO)
4.3 37.5 2.2 -34.9 -1,302.3 -312.4 -- 7.6
Pieris Pharmaceuticals (PIRS)
13.3 21.1 1.4 -16.0 -1,156.1 -83.5 -- 1.1

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Virios Therapeutics (VIRI)

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1,...  a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.  Read more

  • Chairman & CEO

    Mr. Gregory Duncan

  • Chairman & CEO

    Mr. Gregory Duncan

  • Headquarters

    Alpharetta, GA

  • Website

    https://www.virios.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Virios Therapeutics (VIRI)

The share price of Virios Therapeutics Inc (VIRI) is $2.74 (NASDAQ) as of 10-Dec-2024 09:30 EDT. Virios Therapeutics Inc (VIRI) has given a return of -71.31% in the last 3 years.

Since, TTM earnings of Virios Therapeutics Inc (VIRI) is negative, P/E ratio is not available.
The P/B ratio of Virios Therapeutics Inc (VIRI) is 3.33 times as on 10-Dec-2024, a 26 discount to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
--
--
2022
--
--
2021
--
--
2020
--
--
2019
--
--

The 52-week high and low of Virios Therapeutics Inc (VIRI) are Rs -- and Rs -- as of 17-May-2026.

Virios Therapeutics Inc (VIRI) has a market capitalisation of $ 0 Mln as on 10-Dec-2024. As per SEBI classification, it is a Small Cap company.

Before investing in Virios Therapeutics Inc (VIRI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.